A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
about
Oral deferiprone for iron chelation in people with thalassaemiaBiopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.Prion protein promotes kidney iron uptake via its ferrireductase activity.Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.An update on iron chelation therapyToward optimizing the use of deferasirox: potential benefits of combined use with deferoxamineCardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapyCurrent approach to iron chelation in children.A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.Safety profiles of iron chelators in young patients with haemoglobinopathies.The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
P2860
Q24200309-E73B95C2-07E5-4C23-BB7F-F3C1BDF3A62DQ33783224-4CE2B381-FFC7-4E04-A381-0966F1122376Q34083003-43AA1A0B-1D23-4EA2-BE61-88A00F69AFB2Q35077670-EFE68786-7407-462B-9C3D-BCD4D86734E9Q35126635-DA8A3363-EA2D-4155-A28E-2CA8D38AF738Q35906193-017D49EC-09E0-447B-99FD-1A7CC97198D3Q36393446-DD6006E5-DDF4-4561-9D5D-C8C999244E7AQ36498403-9E9AF0FD-AAD2-48EA-A73C-F7E2031D4026Q36690349-F19399B6-66CE-4BF0-A96A-7DFBDB583B1FQ38197269-16478894-9154-4D56-AE2B-7FE4A294B72BQ38259421-498DCDFE-CA8A-47BA-ADFB-77E56E3307DDQ38540491-3D4C865C-06B1-4996-8801-22007CC21253Q38650293-DF410C79-19B3-406B-A98C-CEBE91C3E922Q38868675-7C8B0D60-C2B5-43E2-8DDC-3C69A3D6D23DQ39022073-D7D1ADC2-146D-4FD4-B107-13EA1A2CD4B2Q39260564-717197F0-A3DA-4629-90D4-5B85EE544482Q40896307-F2D77B49-F4C4-4442-A6B4-2022A6AAFD86Q41562000-0F826DEB-B635-4C7E-9DBB-7CD4676EACA7Q42183461-C38E28FD-02E6-451E-A926-470BFC48AFE8Q42956247-AEFB9250-17B5-432A-81A1-4EA77925C34FQ48379687-F8CE3EF0-BA71-40C6-8F79-430123FDE6E0Q51040955-5E331950-F1B6-4786-BEC0-5879AE7E44E4Q53995645-CDFC2A0D-A93A-40E7-9C14-14A271CB500FQ56389520-4E2781C7-90A2-4AD6-A1D7-5F7050DB0C50
P2860
A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A randomized controlled 1-year ...... tients with thalassemia major.
@en
A randomized controlled 1-year ...... tients with thalassemia major.
@nl
type
label
A randomized controlled 1-year ...... tients with thalassemia major.
@en
A randomized controlled 1-year ...... tients with thalassemia major.
@nl
prefLabel
A randomized controlled 1-year ...... tients with thalassemia major.
@en
A randomized controlled 1-year ...... tients with thalassemia major.
@nl
P2093
P356
P1433
P1476
A randomized controlled 1-year ...... tients with thalassemia major.
@en
P2093
Arthur Zimmermann
Aysen Terzi
Chantal Manz
Deniz Nart
Gareth Ellis
Nurten Cetiner
Yesim Aydinok
Zulal Ulger
P304
P356
10.3324/HAEMATOL.11414
P577
2007-12-01T00:00:00Z